CyclopharmASX:CYC 46 Current Ratio is 2.53 as of Dec. 2025, which is 25% below its 10-year median of 3.36. GuruFocus rates ASX:CYC with a GF Score™ of 46/100 and a GF Value™ of A$0.84 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 118 Medical Distribution companies, Cyclopharm ranks better than 83.05% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Cyclopharm's current ratio for the quarter that ended in Dec. 2025 was 2.53.
Cyclopharm has a current ratio of 2.53. It generally indicates good short-term financial strength.
The historical rank and industry rank for Cyclopharm's Current Ratio or its related term are showing as below:
ASX:CYC'
s Current Ratio Range Over the Past 10 Years
Min: 2.53 Med: 3.36 Max: 5.83
Current: 2.53
During the past 13 years, Cyclopharm's highest Current Ratio was 5.83. The lowest was 2.53. And the median was 3.36.
ASX:CYC's Current Ratio is ranked better than 83.05% of 118
companies
in the Medical Distribution industry
Industry Median: 1.395
vs ASX:CYC: 2.53
Cyclopharm (ASX:CYC) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Cyclopharm Current Ratio Related Terms
Cyclopharm Current Ratio Historical Data
* Premium members only.
The historical data trend for Cyclopharm's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CYC vs MCK, COR, CAH: Current Ratio Comparison
For the Medical Distribution subindustry, Cyclopharm's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cyclopharm Current Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Cyclopharm's Current Ratio distribution charts can be found below:
* The bar in red indicates where Cyclopharm's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyclopharm (ASX:CYC) has a Current Ratio of 2.53 as of Dec. 2025. This is 25% below median its historical median of 3.36. Over the past decade, Cyclopharm's Current Ratio has ranged from 2.53 to 5.83. According to the industry distribution chart, Cyclopharm ranks #20 out of 118 companies in the Medical Distribution industry, placing it in the top 16.9%.
Is Cyclopharm's Current Ratio too high?
Cyclopharm's current Current Ratio of 2.53 is 25% below median its 10-year median of 3.36. Over the past 10 years, this metric has ranged from a low of 2.53 to a high of 5.83. The Medical Distribution industry median Current Ratio is 1.40. Cyclopharm's value of 2.53 is 81.4% above this industry median. Based on the distribution chart, Cyclopharm ranks #20 out of 118 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Cyclopharm has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cyclopharm's Current Ratio compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Cyclopharm ranks #20 out of 118 companies for Current Ratio. This places Cyclopharm in the top 17% of its industry — outperforming the majority of peers. The industry median Current Ratio is 1.40. Cyclopharm's value of 2.53 is 81.4% above this benchmark. Historically, Cyclopharm's own Current Ratio has ranged from 2.53 to 5.83 over the past decade. While the company's 10-year median is 3.36 vs. the industry median of 1.40, Cyclopharm has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Distribution company?
The median Current Ratio among Medical Distribution companies is 1.40, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cyclopharm's current Current Ratio of 2.53 is 81.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Distribution industry, the median Current Ratio is 1.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cyclopharm's current Current Ratio is 2.53, which is 25% below median its own 10-year median of 3.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyclopharm stock overvalued right now?
Based on GuruFocus' analysis, Cyclopharm (ASX:CYC) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.84, compared to a current price of A$0.50 — trading 40.5% below its estimated fair value. The current Current Ratio is 2.53, which is 25% below median its 10-year median of 3.36 and 81.4% above the Medical Distribution industry median of 1.40. Cyclopharm's overall GF Score™ is 46/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Cyclopharm (ASX:CYC), the current Current Ratio is 2.53 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cyclopharm (ASX:CYC) Overvalued in 2026?
Based on GuruFocus' analysis, Cyclopharm stock appears to be undervalued.
The current stock price of A$0.50 is trading 40.5% below its estimated GF Value™ of A$0.84.
GuruFocus considers Cyclopharm to be Possible Value Trap.
Key valuation signals for ASX:CYC:
Current Ratio: 2.53 (25% below median its 10-year median of 3.36)
GF Value™: A$0.84 vs. price of A$0.50 (40.5% below fair value)
Industry Position: 81.4% above the Medical Distribution median (#20 of 118)
No single metric tells the full story. See the ASX:CYC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cyclopharm Ltd is a health technology company offering solutions related to functional lung ventilation imaging. Its proprietary product Technegas is a broad-spectrum diagnostic lung imaging technology product for the visualisation of pulmonary ventilation and lung function. The company sells its products to healthcare institutions and medical professionals. Maximum revenue is generated from its Technegas products and services, which include the sale of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. Geographically, the company generates maximum revenue from its business in Europe, and the rest from Asia Pacific, Canada, the USA, and other regions.
46GF Score
Get the complete analysis for ASX:CYC
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CYC has been successfully added to your 
